Focus: HistoSonics is a publicly traded medical device company developing non-invasive, autonomous robotic platforms using histotripsy technology to treat solid tumors and benign conditions. The company is expanding from early clinical validation into multi-indication commercialization across oncology and urology.
Profile data last refreshed 18h ago · AI intelligence enriched 2w ago
High-potential early-stage public device company for commercial, engineering, and clinical professionals seeking platform expansion upside, but limited transparency on clinical depth and financial health warrants due diligence.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for HistoSonics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from HistoSonics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
HistoSonics Secures Taiwan Approval For Edison Histotripsy System - BioPharma APAC
HistoSonics Secures Taiwan Approval For Edison Histotripsy System BioPharma APAC
HistoSonics Secures Taiwan Approval For Edison Histotripsy System - BioPharma APAC
HistoSonics Secures Taiwan Approval For Edison Histotripsy System BioPharma APAC
HistoSonics Receives Landmark TFDA Approval in Taiwan, Accelerating Global Expansion - BioSpace
HistoSonics Receives Landmark TFDA Approval in Taiwan, Accelerating Global Expansion BioSpace
HistoSonics submits Edison histotripsy tech to FDA for kidney tumors - MassDevice
HistoSonics submits Edison histotripsy tech to FDA for kidney tumors MassDevice
HistoSonics Moves to Advance Additional Histotripsy Applications Announcing FDA Submission for Kidney Tumors - BioSpace
HistoSonics Moves to Advance Additional Histotripsy Applications Announcing FDA Submission for Kidney Tumors BioSpace
HistoSonics seeks FDA authorization to expand focused ultrasound system to kidney tumors - Medical Economics
HistoSonics seeks FDA authorization to expand focused ultrasound system to kidney tumors Medical Economics
Showing 6 of 9 news items
Based on last 4 crawl cycles
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo